Drug intelligence / Profile preview

cyclophosphamide + cyclosporine A (Chinese Academy of Medical Sciences)

Development stage
Unknown
Lead developer
Takeda
Modality
Small Molecules
Administration
Intravenous, Oral
01

Overview

Cyclophosphamide is a nitrogen mustard alkylating agent and potent immunosuppressant. In the context of severe aplastic anemia (SAA), it is used to eliminate autoreactive T cells that attack hematopoietic stem cells. This specific regimen, investigated by Dr. Xiaofan Zhu at the Chinese Academy of Medical Sciences, utilizes a moderate dose of cyclophosphamide (30 mg/kg/day for 4 days) in combination with cyclosporine A (a calcineurin inhibitor) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). The study aims to evaluate the efficacy and safety of this moderate-dose approach in children with acquired SAA, potentially offering a less toxic alternative to the traditional high-dose (50 mg/kg/day) cyclophosphamide therapy.

Brand names
CytoxanEndoxanNeoralSandimmune
Other names
Moderate-dose cyclophosphamide
02

Targets

DNA

Beyond the preview

Go deeper on cyclophosphamide + cyclosporine A (Chinese Academy of Medical Sciences).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + cyclosporine A (Chinese Academy of Medical Sciences).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call